Multiplex immunofluorescence analysis combined with digital pathology of mCRPC tumor microarrays confirmed FASN/AR-V7 co-expression in about 80% of mCRCP patients resistant to enzalutamide and abiraterone, highlighting this patient subset as the ideal candidate for the treatment with FASN inhibitors (22). The gene discussed is FASN; the disease is neoplasm.